AnaptysBio Rise 6% After Results From Rheumatoid Arthritis Treatment Rosnilimab

Dow Jones

Jun 04, 2025

By Stephen Nakrosis

Shares of AnaptysBio were trading higher in the after-hours market following results from the company's rosnilimab trial as a treatment for patients with rheumatoid arthritis.

After the bell, the company's shares were trading 6.2% higher, at $25. The stock closed Tuesday's regular session with a 7.5% gain at $23.52.

The company said in a global 424-patient Phase 2b trial, its investigational rosnilimab demonstrated a best-in-disease profile in patients with moderate to severe rheumatoid arthritis. The company also said rosnilimab demonstrated favorable safety and tolerability, particularly when compared to standard of care biologics or Janus kinase inhibitors.

AnaptysBio said its ongoing Phase 2 study for rosnilimab in ulcerative colitis is on track to report initial data in the fourth quarter.

Write to Stephen Nakrosis at stephen.nakrosis@wsj.com

(END) Dow Jones Newswires

June 03, 2025 18:10 ET (22:10 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2540700908"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2540700908\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2540700908?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-04 06:10","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2540700908","market":"other","top_or_hot":-1,"title":"AnaptysBio Rise 6% After Results From Rheumatoid Arthritis Treatment Rosnilimab","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Stephen Nakrosis \n</p>\n<pre>\n \n</pre>\n<p>\n  Shares of AnaptysBio were trading higher in the after-hours market following results from the company's rosnilimab trial as a treatment for patients with rheumatoid arthritis. \n</p>\n<p>\n  After the bell, the company's shares were trading 6.2% higher, at $25. The stock closed Tuesday's regular session with a 7.5% gain at $23.52. \n</p>\n<p>\n  The company said in a global 424-patient Phase 2b trial, its investigational rosnilimab demonstrated a best-in-disease profile in patients with moderate to severe rheumatoid arthritis. The company also said rosnilimab demonstrated favorable safety and tolerability, particularly when compared to standard of care biologics or Janus kinase inhibitors. \n</p>\n<p>\n  AnaptysBio said its ongoing Phase 2 study for rosnilimab in ulcerative colitis is on track to report initial data in the fourth quarter. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Stephen Nakrosis at stephen.nakrosis@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  June 03, 2025 18:10 ET (22:10 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>AnaptysBio Rise 6% After Results From Rheumatoid Arthritis Treatment Rosnilimab</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAnaptysBio Rise 6% After Results From Rheumatoid Arthritis Treatment Rosnilimab\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-06-04 06:10</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Stephen Nakrosis \n</p>\n<pre>\n \n</pre>\n<p>\n  Shares of AnaptysBio were trading higher in the after-hours market following results from the company's rosnilimab trial as a treatment for patients with rheumatoid arthritis. \n</p>\n<p>\n  After the bell, the company's shares were trading 6.2% higher, at $25. The stock closed Tuesday's regular session with a 7.5% gain at $23.52. \n</p>\n<p>\n  The company said in a global 424-patient Phase 2b trial, its investigational rosnilimab demonstrated a best-in-disease profile in patients with moderate to severe rheumatoid arthritis. The company also said rosnilimab demonstrated favorable safety and tolerability, particularly when compared to standard of care biologics or Janus kinase inhibitors. \n</p>\n<p>\n  AnaptysBio said its ongoing Phase 2 study for rosnilimab in ulcerative colitis is on track to report initial data in the fourth quarter. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Stephen Nakrosis at stephen.nakrosis@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  June 03, 2025 18:10 ET (22:10 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2540700908","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2540700908","pubTimestamp":1748988600,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of AnaptysBio were trading higher in the after-hours market following results from the company's rosnilimab trial as a treatment for patients with rheumatoid arthritis.After the bell, the company's shares were trading 6.2% higher, at $25. The stock closed Tuesday's regular session with a 7.5% gain at $23.52.The company said in a global 424-patient Phase 2b trial, its investigational rosnilimab demonstrated a best-in-disease profile in patients with moderate to severe rheumatoid arthritis. The company also said rosnilimab demonstrated favorable safety and tolerability, particularly when compared to standard of care biologics or Janus kinase inhibitors.AnaptysBio said its ongoing Phase 2 study for rosnilimab in ulcerative colitis is on track to report initial data in the fourth quarter.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","ANAB":"Anaptysbio Inc"},"translate_title":"类风湿性关节炎治疗Rosnilimab结果公布后，AnaptysBio股价上涨6%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ANAB":0.9},"content_text":"By Stephen Nakrosis \n\n\n \n\n\n  Shares of AnaptysBio were trading higher in the after-hours market following results from the company's rosnilimab trial as a treatment for patients with rheumatoid arthritis. \n\n\n  After the bell, the company's shares were trading 6.2% higher, at $25. The stock closed Tuesday's regular session with a 7.5% gain at $23.52. \n\n\n  The company said in a global 424-patient Phase 2b trial, its investigational rosnilimab demonstrated a best-in-disease profile in patients with moderate to severe rheumatoid arthritis. The company also said rosnilimab demonstrated favorable safety and tolerability, particularly when compared to standard of care biologics or Janus kinase inhibitors. \n\n\n  AnaptysBio said its ongoing Phase 2 study for rosnilimab in ulcerative colitis is on track to report initial data in the fourth quarter. \n\n\n \n\n\n  Write to Stephen Nakrosis at stephen.nakrosis@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  June 03, 2025 18:10 ET (22:10 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}